Glare Paul, Shariff Imran, Thaler Howard T
1 Pain and Palliative Care Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center , New York, New York.
J Palliat Med. 2014 Jul;17(7):797-802. doi: 10.1089/jpm.2013.0256. Epub 2014 May 28.
Prognostic tools are available to predict if terminally ill cancer patients have days or weeks to live. Tools for predicting the prognosis in ambulatory patients at an earlier stage are lacking. The Number of Risk Factors (NRF) score developed in ambulatory cancer patients receiving palliative radiation therapy may be suitable for this purpose but has not been tested in a palliative care setting.
Our aim was to evaluate the prognostic accuracy of the NRF score in patients referred to a palliative care outpatient clinic at a comprehensive cancer center.
We conducted a retrospective chart review of NRF scores and survival in 300 consecutive, newly referred patients. Measurements included primary cancer type, extent of disease, Karnofsky Performance Scale (KPS) score, and survival duration after first visit. One point was allocated each for cancer other than breast cancer, metastases other than bone, and low KPS score.
Of 300 patients, 236 (79%) had advanced disease. Of those 236, 212 (90%) had a cancer other than breast cancer, 180 (76%) had metastatic disease in sites other than bone, and 64 (27%) had a KPS score <70%. During the 2-year follow-up, 221 (94%) patients died, with overall median survival of 4.9 months (95% confidence interval, 3.9-6.1 months). NRF scores of 0 to 1, 2, and 3 split the sample into subgroups with highly significantly different survival among the groups, with medians 9.0, 4.6, and 2.1 months, respectively (Wilcoxon test χ(2)=43.9, degrees of freedom [df] 2, p<0.0001). A simple parametric model was fit to determine the probability of subgroup members surviving to a certain number of months.
In cancer patients referred to palliative care earlier in their disease trajectory, the NRF score may be a useful prognostic tool. Further validation in other palliative care populations is needed.
已有预后工具可预测晚期癌症患者还剩几天或几周的生命。但缺乏用于预测早期门诊患者预后的工具。在接受姑息性放射治疗的门诊癌症患者中开发的风险因素数量(NRF)评分可能适用于此目的,但尚未在姑息治疗环境中进行测试。
我们的目的是评估NRF评分在综合癌症中心姑息治疗门诊转诊患者中的预后准确性。
我们对300例连续新转诊患者的NRF评分和生存情况进行了回顾性病历审查。测量指标包括原发癌类型、疾病范围、卡氏功能状态量表(KPS)评分以及首次就诊后的生存时间。非乳腺癌、非骨转移和低KPS评分各得1分。
300例患者中,236例(79%)患有晚期疾病。在这236例患者中,212例(90%)患有非乳腺癌,180例(76%)在非骨部位有转移性疾病,64例(27%)的KPS评分<70%。在2年的随访期间,221例(94%)患者死亡,总体中位生存期为4.9个月(95%置信区间,3.9 - 6.1个月)。NRF评分为0至1分、2分和3分将样本分为亚组,各组间生存情况差异极显著,中位数分别为9.0个月、4.6个月和2.1个月(Wilcoxon检验χ(2)=43.9,自由度[df]为2,p<0.0001)。拟合了一个简单的参数模型来确定亚组成员存活至特定月数的概率。
对于在疾病进程中较早转诊至姑息治疗的癌症患者,NRF评分可能是一种有用的预后工具。需要在其他姑息治疗人群中进一步验证。